by Rayner
The best conversations about ophthalmology happen when leading surgeons sit down with their peers and explore topics big and small. Each episode brings together rotating hosts and their invited guests resulting in a mix of invaluable insights and unscripted moments you won’t want to miss. Published by Rayner.
Language
🇺🇲
Publishing Since
1/8/2023
Email Addresses
0 available
Phone Numbers
0 available
April 7, 2025
Join the study Principal Investigators, Paul Singh, Cathy McCabe, and Brian Shafer, as they discuss preliminary findings from their recent study looking at a dropless postoperative surgery regimen including OMIDRIA vs. a standard topical regimen. Discover how using OMIDRIA as part of a dropless regimen can streamline surgical processes, enhance patient compliance, and reduce the burden of topical drops. Learn how this approach not only improves patient outcomes and satisfaction but also increases operational efficiency within clinics by minimizing the time spent on post-operative eye drop management. Learn why now is the ideal time to incorporate a dropless strategy. You’ll hear the compelling initial data, including information addressing common concerns about patient compliance and inflammation control. This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease. Please use clinical judgment when considering treatment. Refer to Rayner product labeling and instructions for use. A dropless approach with OMIDRIA may not suit all patients. Rayner does not recommend specific product combinations. As of March 2025, OMIDRIA is approved in the US and UK. Speakers may be paid Rayner consultants. Rayner®, the Rayner logo, OMIDRIA, and the OMIDRIA logo, are proprietary marks of Rayner. © 2025 Rayner Group, all rights reserved. OMIDRIA podcasts are for the attention of US HCPs only. US-OM-2500001 03/25
February 10, 2025
Professor Graham Barrett, the innovator behind RayOne EMV in partnership with Rayner, joins Mr Alastair Stuart, Medical Director of Optegra UK, in his clinic to discuss why he frequently chooses RayOne EMV for his patients. Mr Stuart shares both his clinical expertise - covering patient selection, calculations, and outcomes - and his personal experience of recommending the lens for his own father’s cataract surgery. Together, they examine the lens' advantages in managing spherical aberration, its benefits for post-corneal refractive patients, and how it compares to other intraocular lenses (IOLs) in the field.
January 9, 2025
Dr Ben LaHood, Prof Damien Gatinel, and Sam Carter discuss the latest advancements in RayTrace, including the integration of Gatinel’s PEARL-DGS formula. This new feature leverages AI to improve RayTrace’s predictive accuracy and optimise results by factoring in IOL curvature and effective lens position. Bios: Dr Ben LaHood, refractive cataract and laser vision correction surgeon from Australia, has gained international recognition for his extensive research on astigmatism management and biometry, which is regularly shared around the world. Additionally, Dr Ben LaHood is the host of two widely popular ophthalmology-themed podcasts. Professor Damien Gatinel is the Head of the Department of Refractive and Anterior Segment Surgery at the Rothschild Foundation Hospital in Paris. He is the co-inventor of the first trifocal IOL, and devised a new classification for HOAs in his applied mathematics PhD thesis. With his colleague, Alain Saad, he developed an AI system for the detection of ectasia-susceptible eyes, the SCORE analyser. Sam Carter is the Head of Clinical Planning and Outcomes at Rayner. Based in Kuala Lumpar, Malaysia, he brings experience from previous roles at Lenstec UK, Topcon GB Ltd, and Zeiss Medical Technology. Carter additionally holds a 2023-2024 Post Graduate Diploma in Cataract and Refractive Surgery from Ulster University, one of only a handful of non-ophthalmologists to gain this certification. This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. Not all Rayner products are available in all countries. © 2025 Rayner Group, all rights reserved. Rayner, RayTrace and RayPRO are proprietary marks of Rayner. All other trademarks are property of their respective owners. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.
